Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?Zacks Investment Research • 06/18/25
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?The Motley Fool • 06/18/25
The story of how Novo Nordisk will lose billions because it didn't pay a couple of hundred dollarsMarket Watch • 06/16/25
Novo Nordisk plans to start late-stage trials for experimental obesity drug amycretinReuters • 06/12/25
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical developmentGlobeNewsWire • 06/12/25
ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes careGlobeNewsWire • 06/10/25